4 stories
Oral Wegovy is Novo Nordisk's reformulated, higher-dose oral semaglutide for chronic weight management. The launch sits in a tight competitive frame with Lilly's Foundayo (orforglipron), with both targeting the same patient base from different chemistry angles.
Launch pricing: 1.5mg starter dose at $149/month on NovoCare, 4mg dose moving from $149 to $199/month effective April 15, 2026. The 9mg and 25mg maintenance doses sit at $299/month. Indirect comparisons against Foundayo have suggested oral Wegovy may produce greater weight loss with fewer GI discontinuations, though Foundayo leads on HbA1c.
Stories here cover launch tracking, payer coverage, and head-to-head comparisons. See #wegovy for the broader Wegovy thread, #oral-glp-1 for the class, and #foundayo for the head-to-head.
Detailed comparison of Lilly's Foundayo (orforglipron) and Novo's oral Wegovy. Foundayo offers no food/water restrictions; oral Wegovy has brand familiarity and head start. Wall Street predicts slower initial Foundayo uptake.
The ACHIEVE-3 trial in The Lancet showed Eli Lilly's Foundayo (orforglipron) superior on HbA1c, while Novo Nordisk's oral Wegovy may have an edge in weight-loss efficacy.
GoodRx announced oral semaglutide availability via its telemedicine platform at $149 for lower doses, matching Novo Nordisk pricing and intensifying the GLP-1 price war.
The 25-mg oral semaglutide formulation broadens GLP-1 access for chronic weight management, with pharmacists playing a key role in patient counseling and adherence support.